WHO stops hydroxychloroquine, Lopinewe/Litonavi branch tests

GENEVA, July 4 (Xinhua Liu Qu) The World Health Organization announced on the 4th that it will stop the trials of the two branches of hydroxychloroquine and Lopinave/Litonave in its "Unity Trial" project, on the grounds that the death rate of new crown inpatients in these branch trials has barely or completely decreased.
WHO said in a statement the same day that the results showed that hydroxychloroquine and the Lopinave/Litonave branches had almost or not reduced the death rate of new crown hospitalizations compared to the standard nursing branch. Combined with the results of the trials and the assessment of the evidence at the second New Crown Global Research Forum held this week, the organization finally decided to stop the trials of the two branches.
WHO stresses that this decision applies only to "solidarity trials" for new crown inpatients and does not affect other research assessments of the use of hydroxychloroquine or lopinave/litonave in non-hospitalized patients, or as an assessment of pre- or post-exposure prevention of new crowns.
WHO said that while the results of both branches did not explicitly show an increase in patient deaths, there were still some relevant "safety signals" in clinical laboratory results in the French-led Discovery Trial, an add-on to the Solidarity Trial.
"Unity Trial" project, launched by WHO in March, aims to find effective treatments for inpatients by comparing multiple new coronary therapies. Unity Has recruited approximately 5,500 patients from 39 countries and regions to participate.